Trial Profile

Expanded Access Program for TLX250-CDx

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 03 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Girentuximab Zr-89 (Primary)
Indications Cancer
Focus Diagnostic use
Sponsors Telix Pharmaceuticals

Most Recent Events

29 Apr 2024 According to a Telix pharmaceutical media release, first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix1) positron emission tomography (PET) imaging in clear cell renal cell carcinoma (ccRCC).
24 Oct 2023 As per MR 9401295, compassionate use access programs are active in Europe and Australia. this CTP has mentioned location as unknow, so I added Aus and updated accordingly. Since source mentions "programmers " it seems there are multiple studies so created another CTP for Europe location
18 Oct 2023 Status changed from planning to recruiting, according to a Telix pharmaceutical media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com